Compare BBSI & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBSI | ODTX |
|---|---|---|
| Founded | 1965 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 781.3M | 875.1M |
| IPO Year | 1994 | 2025 |
| Metric | BBSI | ODTX |
|---|---|---|
| Price | $31.33 | $20.86 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $42.67 | N/A |
| AVG Volume (30 Days) | ★ 260.8K | 129.6K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | ★ 5.05 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $920,432,000.00 | N/A |
| Revenue This Year | $6.59 | N/A |
| Revenue Next Year | $6.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.50 | N/A |
| 52 Week Low | $25.33 | $15.10 |
| 52 Week High | $49.65 | $23.08 |
| Indicator | BBSI | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.42 | 56.42 |
| Support Level | $26.86 | $15.10 |
| Resistance Level | $31.99 | N/A |
| Average True Range (ATR) | 1.47 | 1.69 |
| MACD | -0.89 | 0.09 |
| Stochastic Oscillator | 7.95 | 57.36 |
Barrett Business Services Inc is a provider of business management solutions for small and mid-sized companies through a platform that combines management consulting expertise with human resource tools to help business owners manage and operate their businesses more effectively. The company has two categories of services: Professional Employer Services (PEO) and Staffing. The majority of revenue is derived from the Professional Employer Services segment, which provides clients with human resource advisory services, HRIS access, retirement plans, a learning management system, and a web-based technology platform, myBBSI.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.